Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company.

In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.

[2] Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use.

[3] Ruboxistaurin is an inhibitor of protein kinase C-beta.

This drug article relating to the gastrointestinal system is a stub.